Supernus Pharmaceuticals Files 8-K
Ticker: SUPN · Form: 8-K · Filed: 2024-06-17T00:00:00.000Z
Sentiment: neutral
Topics: corporate-action, financials
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K for shareholder votes and financials.
AI Summary
Supernus Pharmaceuticals, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing does not contain specific details on the votes or financial figures within the provided text.
Why It Matters
This filing indicates Supernus Pharmaceuticals is engaging in formal corporate actions requiring shareholder input and is providing necessary financial disclosures.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- June 14, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-35518 (commission_file_number) — SEC File Number
- 20-2590184 (irs_number) — I.R.S. Employer Identification No.
- 9715 Key West Ave (address) — Principal Executive Offices
- Rockville (city) — Principal Executive Offices
- MD (state) — Principal Executive Offices
- 20850 (zip_code) — Principal Executive Offices
- ( 301 ) 838-2500 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Supernus Pharmaceuticals' security holders?
The provided text of the 8-K filing does not specify the exact matters submitted to a vote of security holders.
What are the key financial statements or exhibits included in this 8-K filing?
The filing indicates that Financial Statements and Exhibits are included, but the specific details of these documents are not present in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 14, 2024.
What is Supernus Pharmaceuticals, Inc.'s principal executive office address?
Supernus Pharmaceuticals, Inc.'s principal executive office is located at 9715 Key West Ave, Rockville, MD 20850.
What is the SEC file number for Supernus Pharmaceuticals, Inc.?
The SEC file number for Supernus Pharmaceuticals, Inc. is 001-35518.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-17 16:15:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq S
Filing Documents
- tm2417381d1_8k.htm (8-K) — 35KB
- 0001104659-24-072272.txt ( ) — 203KB
- supn-20240614.xsd (EX-101.SCH) — 3KB
- supn-20240614_lab.xml (EX-101.LAB) — 33KB
- supn-20240614_pre.xml (EX-101.PRE) — 22KB
- tm2417381d1_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 14, 2024 Supernus Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The definitive proxy statement pertaining to the Annual Meeting was previously filed by the Company with the Securities and Exchange Commission on April 29, 2024. As of the close of business on April 18, 2024, there were 54,973,754 shares of common stock outstanding and entitled to vote. The tabulation of votes for each proposal voted on by the stockholders was as follows: Proposal 1: Election of Class III Directors, each to serve until the Annual Meeting of the Company in 2027. Name Votes For Votes Withheld Broker Non-Votes Georges Gemayel, Ph.D 48,410,580 2,121,505 1,945,574 Bethany L. Sensenig 48,568,282 1,963,803 1,945,574 Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers. Votes For Votes Against Abstain Broker Non-Votes 48,217,539 2,290,237 24,309 1,945,574 Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2024. Votes For Votes Against Abstain Broker Non-Votes 52,182,042 272,906 22,711 0 Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the plan and make certain technical updates. Votes For Votes Against Abstain Broker Non-Votes 45,522,166 4,972,675 37,244 1,945,574
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 104 — The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: June 17, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer